BioLab Holdings

What BioLab Holdings does

BioLab Holdings, Inc. is a Mesa, Arizona-based privately held medical manufacturer specializing in advanced wound care and regenerative medicine solutions. The company develops, manufactures, and distributes a portfolio of tissue allografts and synthetic wound care products — including the Membrane Wrap™ amnion-based product line (single-, dual-, and triple-layer variants plus ocular and hydrated formats), the Microlyte® SAM fully synthetic antimicrobial matrix, Microlyte® PainGuard™ with lidocaine delivery, and the Mānuka honey-based APIS® line distributed under partnership with SweetBio. The technology stack extends into adjacent modalities through investments in cold atmospheric plasma (plasmapax® via terraplasma medical) and fish collagen biomaterials (Real Collagen GmbH), with multiple active clinical trials (CAMP RWE, BIOCAMP, CAMPR-II, BIO-SEE) generating evidence for chronic wound indications including diabetic foot ulcers and venous leg ulcers.

BioLab operates through two wholly owned subsidiaries — BLS Labs, LLC (tissue banking: donor screening, recovery, processing, storage, distribution) and BLS Sales & Marketing, LLC — both holding AATB Level A accreditation. Revenue is generated through one-time sales of medical devices and biologics to healthcare providers, wound care centers, and a national distribution network of channel partners, augmented by a Product Reimbursement Team that achieves a 96% approval rate at second-level payer appeals. Pricing is quote-based and not publicly disclosed.

The leadership team combines deep medical device and biologics experience, with the CEO and Chairman co-founding the company after a career pivot from telecommunications. Strategic direction emphasizes inorganic portfolio expansion (four partnerships/investments within roughly a year), clinical evidence generation, operational scaling (37 hires in the past year), and geographic breadth including initial Canada registration alongside U.S. operations across multiple state licenses.

Name

BioLab Holdings

Legal name

BioLab Holdings, Inc.

Website

https://biolabholdings.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Short description

BioLab Holdings is a Mesa, Arizona-based medical manufacturer that develops and distributes advanced wound care products — amnion membrane allografts, synthetic antimicrobial matrices, and bioengineered dressings — serving healthcare providers, wound care centers, and national distribution partners across the U.S.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL)

Keywords

• Wound care products
• Medical devices
• Tissue allografts
• Antimicrobial matrices
• Regenerative medicine

Headquarters

HQ city

Mesa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device and Tissue Product Sales: Sale of wound care medical devices and biologics including membrane products, synthetic antimicrobial matrices, and related wound care solutions to healthcare providers and patients through distribution network.
2. Reimbursement Support Services: Providing reimbursement and insurance verification services to support providers with claims resolution and payer negotiations, with 96% approval rate at second-level appeal stage.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

BioLab Holdings is a Phoenix-based medical manufacturer that develops, produces, and distributes advanced wound care products including amnion-based membrane allografts (Membrane Wrap line), synthetic antimicrobial matrices (Microlyte® SAM™ and PainGuard™), and APIS® bioengineered wound dressings, supported by a national distribution network and dedicated reimbursement support services for healthcare providers treating chronic wounds.

Differentiator

Problem solved

Functional benefit

Brands

• RealRecovery: A cosmetic companion product addressing patient needs.
• Microlyte SAM
• Microlyte PainGuard
• APIS
• Membrane Wrap
• Membrane Wrap Lite
• Tri-Membrane Wrap
• Membrane Wrap Hydro
• Membrane Wrap Amniotic Hydro
• Membrane Lite Restore Ocular

Products and services

• Membrane Wrap™ Product Line (Amnion-based Tissue Allografts) Minimally manipulated amnion-amnion human tissue allografts used as protective barriers and coverings for chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and ocular surface protection. All variants are donor-screened, tested for infectious diseases, and terminally sterilized; processed under AATB Level A accreditation.
• Microlyte® SAM™ Synthetic Antimicrobial Matrix Fully synthetic, ultra-thin porous matrix made of bioresorbable polymers designed to mimic human ECM, containing ionic and metallic silver at low, non-toxic levels providing 99.99% reduction in microbial burden. Conforms to wound-bed micro-crevices and maintains a moist healing environment for chronic wound care.
• Microlyte® PainGuard™ (Synthetic Antimicrobial Matrix with Lidocaine) Synthetic antimicrobial matrix with ionic and metallic silver providing 99.99% microbial reduction, combined with uniform unit-dose lidocaine HCl release for simultaneous pain relief. Over 80% of lidocaine is released within the first 30 minutes, providing antimicrobial action plus localized pain management for wound care patients.
• APIS® Bioengineered Wound Care Bioengineered wound care solution combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite for chronic and acute wounds. Distributed by BioLab Holdings for hospitals, wound care centers, and physician offices nationwide; products are FDA-cleared and Medicare-covered.
• plasmapax® Cold Atmospheric Plasma Device Portable cold atmospheric plasma (CAP) device for antimicrobial treatment in wound care, dermatology, and podiatry settings. The device has been used in over 100,000 treatments globally prior to its U.S. commercial expansion via BioLab Holdings' partnership with terraplasma medical, with FDA clearance as the goal for U.S. market entry.

Quantifiable outcome

• 96% approval rate at second-level appeal stage for reimbursement claims
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and strategic.

• SweetBio, Inc.coreChannel Partner/ Reseller/ Distributor · 27 April 2026Strategic distribution partnership to expand access to SweetBio's APIS® bioengineered wound care products through BioLab's national distribution network. APIS® is the first and only wound care solution combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. Products are already Medicare-covered and FDA-cleared, strengthening BioLab's continuum-of-care portfolio.
• terraplasma medical GmbHcoreStrategic or Co-development Partner · 24 October 2025Investment and partnership to commercialize plasmapax®, a portable cold atmospheric plasma (CAP) device for antimicrobial treatment in wound care, dermatology, and podiatry. Device has been used in over 100,000 treatments globally and is pursuing FDA clearance. Collaboration aims to expand U.S. market access leveraging BioLab's distribution network.
• Real Collagen GmbHstrategicStrategic or Co-development Partner · 7 March 2025Investment and partnership to create new wound care products using fish collagen. This partnership will allow BioLab to develop innovative wound care solutions using alternative collagen sources.

Scale indicators5 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Organogenesis Holdings: Public regenerative medicine company (NASDAQ: ORGO) selling amniotic membrane products (e.g., Apligraf, Dermagraft, PuraPly) directly competitive with BioLab's Membrane Wrap and Microlyte lines in chronic wound care.
• MiMedx Group: Pioneer in dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for diabetic foot ulcers, venous leg ulcers, and surgical wounds, competing head-to-head with BioLab's Membrane Wrap portfolio.
• Integra LifeSciences: Public medical device company with a sizable regenerative tissue and wound care franchise (Integra Dermal Regeneration Template, AmnioExcel), overlapping BioLab's amnion-based skin substitute category.
• MTF Biologics: Non-profit tissue bank and biologics manufacturer supplying amniotic membranes and skin allografts with AATB accreditation comparable to BioLab's BLS Labs subsidiary in tissue-recovery operations.
• Vivex Biologics: Emerging regenerative medicine company selling amniotic and umbilical tissue products (AmnioFix, Cyma) overlapping BioLab's Membrane Wrap positioning in chronic and surgical wound care.

Broad incumbents

• Smith & Nephew: Global medical device incumbent with large Advanced Wound Management and Skin Bioactive franchises competing with BioLab on antimicrobial dressings, biologics, and chronic wound solutions.
• ConvaTec: Global wound care and ostomy specialist with hydrocolloids, antimicrobial dressings, and biologic skin substitutes that compete broadly in the chronic-wound market BioLab serves.
• Coloplast: European medical products incumbent with a dedicated wound & skin care business (Biatain, Convatec-comparable portfolios) addressing the same hospital and home-care chronic wound segments as BioLab.
• 3M Health Care (formerly Acelity/KCI): Owns the KCI negative pressure wound therapy and advanced wound care lines (V.A.C., Snap, Promogran) commonly combined with skin substitutes like BioLab's membrane products in chronic-wound pathways.
• Mölnlycke Health Care: Global wound care and surgical solutions company (Mepilex, Mepitel) competing with BioLab's antimicrobial and protective dressings in both hospital and outpatient chronic-wound channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biolab-holdings

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioLab Holdings